Table 3.
Baseline subject characteristics.
| All Subjects (n=18) | ILA Absent (n=11) | ILA Present (n=7) | p | |
|---|---|---|---|---|
| Female, n (%) | 11 (61%) | 7 (64%) | 4 (47%) | 1.00 |
| Age, years | 52 (47–57) | 49 (38–56) | 52 (47–63) | 0.36 |
| RA symptom duration, years | 1 (0.2–3) | 1 (1–2) | 1 (1–2) | 0.68 |
| Ever smoker, n (%) | 7 (39%) | 4 (57%) | 3 (43%) | 1.00 |
| Methotrexate use (current or prior), n (%) | 11 (61%) | 7 (64%) | 4 (47%) | 1.00 |
| Biologic agent use (current or prior), n (%) | 10 (56%) | 7 (64%) | 3 (43%) | 0.63 |
| FEV1, % predicted | 105 (98–110) | 105 (101–109) | 95 (93–114) | 0.41 |
| FEV1/FVC ratio | 77 (75–81) | 79 (77–81) | 75 (68–82) | 0.36 |
| TLC, %predicted | 107 (96–112) | 109 (103–112) | 96 (92–112) | 0.17 |
| DLCO, % predicted | 82 (74–90) | 81 (74–92) | 83 (67–87) | 0.34 |
| HRCT score | 0 (0–3) | 0 (0–0) | 5 (2–20) | n/a |
All values are presented as median (interquartile range) unless otherwise noted.
“ILA present” is defined as having total score of 1 or higher on baseline HRCT. “ILA absent” is defined as baseline HRCT total score of 0.
ILA: interstitial lung abnormalities; RA: rheumatoid arthritis; HRCT: high-resolution computed tomography; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusion capacity of lungs for carbon monoxide.